Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
The Supreme Court will hear a plea on December 3 concerning the supply and quality of anti-retroviral (ARV) drugs for HIV ...
Self-reported measures of antiretroviral adherence vary greatly in recall time periods and response tasks. To determine which time frame is most accurate, we compared 3-, 7-day, and 1-month ...
Southern Eye on MSN
ARV probe spotlights ‘sophisticated’ racket at Masvingo hospital
The medical superintendent at Masvingo Provincial Hospital has called on the police to investigate what he described as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback